G.D. Searle & Company marketed Bextra, also known as Valdecoxib, as a pain-relieving drug. Pfizer subsequently acquired Searle and marketed Bextra worldwide until the drug was withdrawn from the market in 2005.
Pfizer manufactured Bextra in order to replace Pfizer’s other pain relieving drug, Celebrex, after concerns were raised about the safety of Celebrex. Bextra, an anti-inflammatory drug, is used to treat osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. Vioxx, a similar drug with similar complications, is part of the same class of pain medications as Bextra and Celebrex, known as Cox-2 inhibitors.
Bextra is linked to an increased risk of heart attack, stroke and sometimes fatal skin reactions such as Stevens Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
Symptoms caused by Bextra may include, but are not limited to:
- Skin rash
- Mucosal lesions